MODERN POSSIBILITIES OF INCREASING THE EFFECTIVENESS OF COMPLEX PHARMACOTHERAPY OF CHRONIC BACTERIAL PROSTATITIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: to compare the effectiveness of standard antimicrobial monochemotherapy and two modes of combined pharmacotherapy with the additional administration of various antioxidants in patients with chronic bacterial prostatitis (CBP). Material and methods. 90 patients with CBP aged 24-46 years (mean age 38.2±1.4 years) were examined (main group) and 30 clinically healthy men aged 20-45 years (average age 35.5±1.5 years) (control group). All men before and after treatment were surveyed using the CPSI-QL questionnaire, standard bacteriological and cytological studies, and parameters of the oxidative status of prostatic secretion (the amount and activity of reactive oxygen species (ROS), the level of diene conjugates, malondialdehyde, zinc, superoxide dismutase (SOD) activity) were studied. The studies were conducted in 3 groups of patients. Group 1 (n=15) received levofloxacin 500 mg / day orally for 28 days. Group 2 (n=15) received levofloxacin 500 mg /day orally in combination with zinc picolinate 22 mg / day orally for 28 days. Group 3 (n=15) received levofloxacin 500 mg /day orally in combination with L-carnitine tartrate 1000 mg / day orally for 28 days. Results and discussion. Group 1 demonstrated the worst results in terms of microbiological efficacy, dynamics of normalization of clinical and laboratory parameters, oxidative status of the prostate gland and tolerability of treatment. According to all these characteristics, the results of pharmacotherapy in groups 2 and 3 were significantly better than group 1 (p<0.05) with an unreliable difference between the results (p<0.1). Conclusion. Additional personalized administration of antioxidants (zinc or L-carnitine) to etiotropic antimicrobial chemotherapy significantly improves clinical and laboratory results of CBP pharmacotherapy, while reducing the frequency of side effects.

Full Text

Restricted Access

About the authors

O. I Bratchikov

Kursk State Medical University

Email: bratov45@mail.ru
Ph.D., MD, professor, academician of RAS, honored physician of Russian Federation, Head of the Department of Urology Kursk, Russia

P. A Dubonos

Kursk State Medical University

Email: v-utkin@rambler.ru
Ph.D. student at the Urologic Department Kursk, Russia

I. A Tyuzikov

Medical Center «Tandem-Plus»

Email: phoenix-67@list.ru
urologist and andrologist, Ph.D., professor of the Russian Academy of Natural History Yaroslavl, Russia

Yu. A Zhilyaeva

Kursk State Medical University

Email: uliazhilyaeva85@yandex.ru
associate professor at the Department of Internal Medicine No2, Ph.D. Kursk, Russia

References

  1. Комментарии к клиническим рекомендациям. Урология/под ред. Д.Ю. Пушкаря. М.: «ИД «АБВ-пресс», 2020; 500 с.
  2. Урология. Национальное руководство/под ред. Н.А. Лопаткина. М.: ГЭОТАР-Медиа, 2009; 1024 с.
  3. Простатит/под ред. П.А. Щеплева. М.: МЕДпресс-информ, 2007; 224 с.
  4. Кульчавеня Е.В., Неймарк А.И. Простатит. Диагностика и лечение. М.: ГЭОТАР-Медиа, 2010; 256 с.
  5. Bonkat G., Bartoletti R., Bruyère F., Cai T. et al. EAU Guidelines on Urological Infections. European Association of Urology.Netherlands, 2022; 78 р.
  6. Молочков В.А., Ильин И.И., Молочкова Ю.В. Хронический уретрогенный простатит. М.: ООО «ИПЦ «Маска», 2015; 302 с.
  7. Тюзиков И.А., Греков Е.А. Калинченко С.Ю., Мартов А.Г. Оптимизация диагностики воспалительных заболеваний предстательной железы на основе междисциплинарного подхода. Экспериментальная и клиническая урология. 2013;1:44-51.
  8. Sandhu J., Tu H.Y.V. Recent advances in managing chronic prostatitis/ chronic pelvic pain syndrome. 2017; 6. doi: 10.12688/f1000research.10558.1.
  9. Khan F.U., Ihsan A.U., Khan H.U., Jana R., Wazir J., KhongorzulP., Waqar M., Zhou X.Comprehensive overview of prostatitis. Biomed Pharmacother. 2017;94:1064-1076.
  10. Roumeguère T., Sfeir J., El Rassy E., Albisinni S., Van Antwerpen P., Boudjeltia K.Z., Farès N., Kattan J., Aoun F. Oxidative stress and prostatic diseases. Mol Clin Oncol. 2017;7(5):723-728.
  11. Polackwich A.S., Shoskes D.A. Chronic prostatitis/chronic pelvic pain syndrome: A review of evaluation and therapy. Prostate Cancer Prostatic Dis. 2016;19:132-138.
  12. Vaz C.V., Marques R., Maia C.J., Socorro S. Aging-associated changes in oxidative stress, cell proliferation, and apoptosis are prevented in the prostate of transgenic rats overexpressing regucalcin. Transl Res. 2015;166: 693-705.
  13. Antioxidants in Andrology (Trends in Andrology and Sexual Medicine)/ G. Balercia, L. Gandini, A. Lenzi, F. Lombardo. 1 st. ed. Switzerland: Springer, 2017; 86 p. ISBN: 978-3319417479.
  14. Ihsan A.U., Khan F.U., Khongorzul P. et al. Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress. Biomed Pharmacother. 2018;106:714-723. doi: 10.1016/j.biopha.2018.06.139.
  15. Paulis G. Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Res Rep Urol. 2018;10:75-87. doi: 10.2147/RRU.S170400.
  16. Cui D., Han G., Shang Y. et al. The effect of chronic prostatitis on zinc concentration of prostatic fluid and seminal plasma: a systematic review and meta-analysis. Curr. Med. Res. Opin. 2015;31(9):1763-1769. doi: 10.1185/03007995.2015.1072707.
  17. Воробьёв А.А. Медицинская и санитарная микробиология. М.: Академия, 2008. 464 с.
  18. Litwin M.S.,McNaughton-Collins M.,Fowler F.J. Jr.,Nickel J.C., Calhoun E.A., Pontari M.A., Alexander R.B., Farrar J.T., O’Leary M. P. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999; 162(2):369-375. doi: 10.1016/s0022- 5347(05)68562-x.
  19. Кишкун А.А. Руководство по лабораторным методам диагностики. М.: ГЭОТАР-Медиа, 2007; 798 с.
  20. White E.H., Zafiriou O., Hill J.H.M. Chemiluminescence of luminol: The chemical reaction. J. Am. Chem. Soc. 1964; 86(6):940-941. doi: 10.1021/JA01059A050.
  21. Faulkner K., Fridovich I. Luminol and lucigenin as detectors for O2-. Free Radic. Biol. Med. 1993;15(4):447-451. doi: 10.1016/0891-5849(93)90044-u.
  22. Стальная И.Д. Метод определения диеновой конъюгации ненасыщенных высших жирных кислот. Современные методы в биохимии. М.: Медицина, 1977; С. 63-64.
  23. Стальная И.Д., Гаришвилли Т.Г. Метод определения малонового диальдегида с помощью тиобарбитуровой кислоты. Современные методы в биохимии. М.: Медицина, 1977; С. 66-68.
  24. Костюк В.А., Потапов А.Н., Ковалева Ж.В. Простой и чувствительный метод определения супероксиддисмутазы, основанный на реакции окисления кверцетина. Вопросы медицинской химии. 1990; 36(2):88-91.
  25. Бекман И.Н. Радиохимия. Т. 7: Радиационная и ядерная медицина: физические и химические аспекты. М.: Издатель Мархотин П.Ю. 2012; 400 с.
  26. Гланц С. Медико-биологическая статистика. М.: Практика. 1999; 459 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies